Vaccinex Expands Access to ActivMAb Antigen Virus Technology
ActivMAb's new "Antigen Virus" application complements drug discovery strategies for complex protein targets, according to Vaccinex CEO. Ongoing partnerships can ...
- Latest
- Trending
ActivMAb's new "Antigen Virus" application complements drug discovery strategies for complex protein targets, according to Vaccinex CEO. Ongoing partnerships can ...
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
Cleveland Clinic and IBM join forces to advance immunotherapy research through AI, unlocking new targets for cancer therapy. #Immunotherapy #AI ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.